Experienced in Hepatitis B

Munevver T. Demir

Kerpener Str. 62, 
Koeln, NW, DE 
Experienced in Hepatitis B
Kerpener Str. 62, 
Koeln, NW, DE 
OverviewLocationsClinical Research

Overview

Munevver Demir practices in Koeln, Germany. Demir is rated as an Experienced expert by MediFind in the treatment of Hepatitis B. Their top areas of expertise are Non-Alcoholic Fatty Liver Disease, Cirrhosis, Nonalcoholic Steatohepatitis (NASH), Thrombectomy, and Endoscopy.

Their clinical research consists of co-authoring 168 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 9 articles in the study of Hepatitis B.

Locations

Kerpener Str. 62, Koeln, NW 50937, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients
Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients
Enrollment Status: Terminated
Publish Date: March 29, 2022
Intervention Type: Drug
Study Drug: Cenicriviroc
Study Phase: Phase 2
View 1 Less Clinical Trial

168 Total Publications

Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis D.
Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis D.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: August 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Demir's expertise for a condition
ConditionClose
    View All 41 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile